Kovitz Investment Group Partners
CORT icon

Kovitz Investment Group Partners’s Corcept Therapeutics CORT Stock Holding History

Kovitz Investment Group Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,426
Closed -$202K – 621
2025
Q3 		$202K Buy
+2,426
New +$176K ﹤0.01% 1337
2025
Q2 		– Sell
-1,808
Closed -$207K – 1364
2025
Q1 		$207K Buy
+1,808
New +$110K ﹤0.01% 1172

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kovitz Investment Group Partners's CORT Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,426 shares — an estimated $202K sold.

Kovitz Investment Group Partners first reported a position in CORT in Q1 2025 and held it in 2 quarters. The position peaked at $207K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 2,426 Corcept Therapeutics shares in Q4 2025, an estimated $202K.
  • Kovitz Investment Group Partners first reported a position in Corcept Therapeutics in Q1 2025 and held it in 2 quarters.
  • Kovitz Investment Group Partners's Corcept Therapeutics position peaked at $207K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.